about
Limiting the access to direct-acting antivirals against HCV: an ethical dilemma.How hepatitis C patients manage the treatment process of pegylated interferon and ribavirin therapy: a qualitative study.Extrahepatic manifestations of HCV: the role of direct acting antivirals.Emerging biological agents for hepatitis C.Cost-effectiveness analysis of ledipasvir/sofosbuvir in patients with chronic hepatitis C: Treatment of patients with absence or mild fibrosis compared to patients with advanced fibrosis.Future complications of chronic hepatitis C in a low-risk area: projections from the hepatitis c study in Northern Norway.Comment on Nuño Solinís R, et al. "Value of Treating All Stages of Chronic Hepatitis C: A Comprehensive Review of Clinical and Economic Evidence".Accuracy of elastography point quantification and steatosis influence on assessing liver fibrosis in patients with chronic hepatitis C.
P2860
Q30244361-E168DC8F-C5C8-45BB-AF62-106C203D0916Q36073408-1C794796-8592-49BF-A209-1D914F005F35Q38684508-C12204E7-D2AF-48DB-A9A5-C3D36103A6D7Q38820156-0D5A2891-BA02-40AA-AFB3-F6F09D0DC1CFQ40302226-A10150EE-333E-4F4B-A3A4-0908EEEACED4Q41711879-84D23CD8-10A3-403E-A24B-CEB0C6CF4E90Q42345870-E7C02C76-D721-4B99-A944-D50C6E218FD1Q53074731-AC85DE38-06B5-46EA-B760-68272C1FC450
P2860
description
2016 nî lūn-bûn
@nan
2016 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
name
Why do I treat my patients with mild hepatitis C?
@en
type
label
Why do I treat my patients with mild hepatitis C?
@en
prefLabel
Why do I treat my patients with mild hepatitis C?
@en
P2860
P356
P1433
P1476
Why do I treat my patients with mild hepatitis C?
@en
P2093
Antonio Craxì
P2860
P356
10.1111/LIV.13011
P478
36 Suppl 1
P577
2016-01-01T00:00:00Z